Esophagectomy for the patients with squamous cell carcinoma of the esophagus after allogeneic hematopoietic stem cell transplantation.
Adult
Esophageal Neoplasms
/ etiology
Esophageal Squamous Cell Carcinoma
/ etiology
Esophagectomy
/ adverse effects
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Male
Middle Aged
Neoplasms, Second Primary
/ etiology
Postoperative Complications
/ prevention & control
Prognosis
Retrospective Studies
Treatment Outcome
Chronic graft-versus-host disease
Esophageal cancer
Esophagectomy
Hematopoietic stem cell transplantation
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
04
06
2019
accepted:
10
09
2019
pubmed:
25
9
2019
medline:
13
3
2020
entrez:
25
9
2019
Statut:
ppublish
Résumé
The number of long-term survivors after allogeneic hematopoietic stem cell transplantation (HSCT) has increased recently. Esophageal squamous cell carcinoma occurs at a particularly high incidence as a secondary cancer after HSCT. However, standard treatment for these patients has not been established yet. The objectives of this study were to investigate outcomes of esophagectomy for esophageal carcinoma developed in HSCT patients, and to provide the appropriate perioperative management. Ten HSCT patients underwent esophagectomy for esophageal squamous cell carcinoma between December 2007 and September 2017 at the National Cancer Center Hospital. The surgical outcomes and long-term prognosis of these patients were reviewed retrospectively. In the former group, 5 of the 7 patients (71.4%) developed pneumonia after esophagectomy, with two of them requiring intubation because of respiratory failure. None of the three patients of the latter group, who received broad-spectrum antibiotics for more than 7 days after the surgery, developed any postoperative complications. The estimated survival probability of these patients at 5 years after the surgery was 53.3%. HSCT patients have an extremely high risk of developing pneumonia after esophagectomy, and the condition can easily become serious. Therefore, broad-spectrum antibiotics should be administered prophylactically to prevent severe pneumonia during the perioperative period in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
The number of long-term survivors after allogeneic hematopoietic stem cell transplantation (HSCT) has increased recently. Esophageal squamous cell carcinoma occurs at a particularly high incidence as a secondary cancer after HSCT. However, standard treatment for these patients has not been established yet. The objectives of this study were to investigate outcomes of esophagectomy for esophageal carcinoma developed in HSCT patients, and to provide the appropriate perioperative management.
METHODS
METHODS
Ten HSCT patients underwent esophagectomy for esophageal squamous cell carcinoma between December 2007 and September 2017 at the National Cancer Center Hospital. The surgical outcomes and long-term prognosis of these patients were reviewed retrospectively.
RESULTS
RESULTS
In the former group, 5 of the 7 patients (71.4%) developed pneumonia after esophagectomy, with two of them requiring intubation because of respiratory failure. None of the three patients of the latter group, who received broad-spectrum antibiotics for more than 7 days after the surgery, developed any postoperative complications. The estimated survival probability of these patients at 5 years after the surgery was 53.3%.
CONCLUSIONS
CONCLUSIONS
HSCT patients have an extremely high risk of developing pneumonia after esophagectomy, and the condition can easily become serious. Therefore, broad-spectrum antibiotics should be administered prophylactically to prevent severe pneumonia during the perioperative period in these patients.
Identifiants
pubmed: 31549271
doi: 10.1007/s10147-019-01549-0
pii: 10.1007/s10147-019-01549-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-88Références
Ann Surg. 2014 Aug;260(2):259-66
pubmed: 24743609
Ann Oncol. 2014 Feb;25(2):435-41
pubmed: 24399081
Biol Blood Marrow Transplant. 2011 Sep;17(9):1352-61
pubmed: 21440654
Transplantation. 1998 Sep 15;66(5):667-70
pubmed: 9753353
Tohoku J Exp Med. 2015;237(1):1-8
pubmed: 26268885
Jpn J Clin Oncol. 2013 Jan;43(1):69-73
pubmed: 23225908
Dis Esophagus. 2016 Jul;29(5):429-34
pubmed: 25809390
Ann Surg Oncol. 2012 Jan;19(1):68-74
pubmed: 21879261
Blood Adv. 2018 Aug 14;2(15):1901-1913
pubmed: 30087108
JAMA. 2010 Apr 28;303(16):1617-24
pubmed: 20424252
Clin Infect Dis. 2011 Feb 15;52(4):427-31
pubmed: 21205990
Jpn J Clin Oncol. 2010 Aug;40(8):805-10
pubmed: 20410055
Dis Esophagus. 2017 Oct 1;30(10):1-8
pubmed: 28859387
Lancet. 2012 May 19;379(9829):1887-92
pubmed: 22552194
Bone Marrow Transplant. 2000 Apr;25(8):895-8
pubmed: 10808212
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90
pubmed: 20932658
Transplantation. 2018 Jan;102(1):21-34
pubmed: 28614192
Int J Oncol. 2014 Feb;44(2):443-50
pubmed: 24317739